# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 10, "J Diabetes", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasJournal> \"J Diabetes\"."
1, PublicationYear, 13, 17, "2016", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasPublicationYear> \"2016\"."
29, Title, 104, 281, "Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasTitle> \"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin : A multinational 24 - week , randomized clinical trial .\"."
2, Linagliptin, 127, 138, "linagliptin", "", 
25, Ethnicity, 142, 147, "Asian", "", "<http://ctro/data#Ethnicity_67970> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_67900> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_67970>."
9, Type2Diabetes, 162, 186, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
113, Precondition, 187, 223, "inadequately controlled by metformin", "", "<http://ctro/data#Population_67900> <http://ctro/data#hasPrecondition> \"inadequately controlled by metformin\"."
14, Metformin, 214, 223, "metformin", "", 
20, Multicenter, 228, 241, "multinational", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
21, Duration, 242, 251, "24 - week", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasCTduration> \"24 - week\"."
22, Randomized, 254, 264, "randomized", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
30, Author, 282, 288, "Wang W", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Wang W\"."
31, Author, 297, 303, "Yang J", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Yang J\"."
32, Author, 312, 318, "Yang G", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Yang G\"."
33, Author, 327, 333, "Gong Y", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Gong Y\"."
34, Author, 342, 349, "Patel S", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Patel S\"."
35, Author, 358, 365, "Zhang C", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Zhang C\"."
36, Author, 374, 383, "Izumoto T", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Izumoto T\"."
37, Author, 392, 398, "Ning G", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasAuthor> \"Ning G\"."
38, China, 514, 519, "China", "", 
39, China, 594, 599, "China", "", 
40, China, 684, 689, "China", "", 
42, Germany, 740, 747, "Germany", "", 
43, UK, 791, 793, "UK", "", 
41, China, 858, 863, "China", "", 
44, Japan, 910, 915, "Japan", "", 
12, Type2Diabetes, 968, 992, "type 2 diabetes mellitus", "", 
11, Type2Diabetes, 995, 999, "T2DM", "", 
228, Ethnicity, 1084, 1093, "Caucasian", "", 
54, ObjectiveDescription, 1125, 1343, "The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasObjectiveDescription> \"The present Phase III randomized placebo - controlled double - blind , 24 - week study evaluated the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin added to metformin in Asian T2DM patients .\"."
24, Randomized, 1147, 1157, "randomized", "", 
45, Placebo, 1158, 1165, "placebo", "", 
51, DoubleBlind, 1179, 1193, "double - blind", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
52, Duration, 1196, 1205, "24 - week", "", 
3, Linagliptin, 1288, 1299, "linagliptin", "", 
15, Metformin, 1309, 1318, "metformin", "", 
53, Ethnicity, 1322, 1327, "Asian", "", 
10, Type2Diabetes, 1328, 1332, "T2DM", "", 
55, NumberPatientsCT, 1363, 1366, "306", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasNumberPatientsCT> \"306\"."
64, Precondition, 1367, 1526, "patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy", "", "<http://ctro/data#Population_67900> <http://ctro/data#hasPrecondition> \"patients ( n  =  265 Chinese ; n  =  24 Malaysian ; n  =  17 Filipino ) , aged 18 - 80 years with HbA1c between ≥ 7 . 0 and ≤ 10 . 0 % and on metformin therapy\"."
26, Ethnicity, 1388, 1395, "Chinese", "", "<http://ctro/data#Ethnicity_67902> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_67900> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_67902>."
27, Ethnicity, 1407, 1416, "Malaysian", "", "<http://ctro/data#Ethnicity_67968> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_67900> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_67968>."
28, Ethnicity, 1428, 1436, "Filipino", "", "<http://ctro/data#Ethnicity_67969> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_67900> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_67969>."
56, MinAge, 1446, 1448, "18", "", "<http://ctro/data#Population_67900> <http://ctro/data#hasMinAge> \"18\"."
57, MaxAge, 1451, 1453, "80", "", "<http://ctro/data#Population_67900> <http://ctro/data#hasMaxAge> \"80\"."
159, Year, 1454, 1459, "years", "", 
58, HbA1c, 1465, 1470, "HbA1c", "", 
59, Percentage, 1500, 1501, "%", "", 
16, Metformin, 1509, 1518, "metformin", "", 
23, Randomized, 1532, 1542, "randomized", "", 
60, AllocationRatio, 1545, 1550, "2 : 1", "", "<http://ctro/data#AllocationRatio_67888> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_67888>."
4, Linagliptin, 1563, 1574, "linagliptin", "", "<http://ctro/data#Medication_67944> <http://ctro/data#hasDrug> <http://ctro/data#Linagliptin>."
61, DoseValue, 1575, 1576, "5", "", "<http://ctro/data#Medication_67944> <http://ctro/data#hasDoseValue> \"5\"."
62, mg, 1579, 1581, "mg", "", "<http://ctro/data#Medication_67944> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
63, Frequency, 1582, 1587, "daily", "", "<http://ctro/data#Intervention_67926> <http://ctro/data#hasFrequency> \"daily\"."
46, Placebo, 1591, 1598, "placebo", "", "<http://ctro/data#Medication_67951> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
17, Metformin, 1608, 1617, "metformin", "", 
18, Metformin, 1650, 1659, "metformin", "", 
164, Randomized, 1685, 1698, "randomization", "", 
166, Mean, 1736, 1740, "mean", "", 
66, HbA1c, 1741, 1746, "HbA1c", "", 
67, TimePoint, 1752, 1760, "baseline", "", 
68, TimePoint, 1767, 1775, "24 weeks", "", 
171, Mean, 1862, 1866, "mean", "", 
69, HbA1c, 1875, 1880, "HbA1c", "", 
71, BaseLineValue, 1881, 1886, "8 . 0", "", "<http://ctro/data#Outcome_67981> <http://ctro/data#hasBaselineValue> \"8 . 0\". <http://ctro/data#Outcome_68013> <http://ctro/data#hasBaselineValue> \"8 . 0\"."
72, SdDevBL, 1891, 1896, "0 . 8", "", "<http://ctro/data#Outcome_67981> <http://ctro/data#hasSdDevBL> \"0 . 8\". <http://ctro/data#Outcome_68013> <http://ctro/data#hasSdDevBL> \"0 . 8\"."
73, Percentage, 1897, 1898, "%", "", 
186, Mean, 1912, 1916, "mean", "", "<http://ctro/data#Mean_68010> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_68008> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_68010>."
75, HbA1c, 1926, 1931, "HbA1c", "", "<http://ctro/data#Endpoint_68008> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
5, Linagliptin, 1949, 1960, "linagliptin", "", 
48, Placebo, 1965, 1972, "placebo", "", 
76, Reduction, 1985, 1991, "0 . 66", "", "<http://ctro/data#Outcome_67981> <http://ctro/data#hasChangeValue> \"0 . 66\"."
78, SdErrorChangeValue, 1996, 2002, "0 . 05", "", "<http://ctro/data#Outcome_67981> <http://ctro/data#hasSdErrorChangeValue> \"0 . 05\"."
77, Reduction, 2009, 2015, "0 . 14", "", "<http://ctro/data#Outcome_68013> <http://ctro/data#hasChangeValue> \"0 . 14\"."
79, SdErrorChangeValue, 2020, 2026, "0 . 07", "", "<http://ctro/data#Outcome_68013> <http://ctro/data#hasSdErrorChangeValue> \"0 . 07\"."
80, Percentage, 2027, 2028, "%", "", "<http://ctro/data#Endpoint_68008> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
47, Placebo, 2046, 2053, "placebo", "", 
82, DiffGroupAbsValue, 2077, 2085, "- 0 . 52", "", "<http://ctro/data#DiffBetweenGroups_68040> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 52\"."
83, SdErrorDiff, 2090, 2096, "0 . 09", "", "<http://ctro/data#DiffBetweenGroups_68040> <http://ctro/data#hasStandardErrorDiff> \"0 . 09\"."
81, Percentage, 2097, 2098, "%", "", 
84, ConfIntervalDiff, 2101, 2152, "95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34", "", "<http://ctro/data#DiffBetweenGroups_68040> <http://ctro/data#hasConfIntervalDiff> \"95 % confidence interval [ CI ] - 0 . 70 , - 0 . 34\"."
85, PvalueDiff, 2155, 2169, "P  <  0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_68040> <http://ctro/data#hasPvalueDiff> \"P  <  0 . 0001\"."
106171, SubGroupDescription, 2177, 2215, "patients with baseline HbA1c ≥ 8 . 5 %", "", "<http://ctro/data#Outcome_68049> <http://ctro/data#hasSubGroupDescription> \"patients with baseline HbA1c ≥ 8 . 5 %\"."
199, HbA1c, 2200, 2205, "HbA1c", "", 
179, Percentage, 2214, 2215, "%", "", 
49, Placebo, 2222, 2229, "placebo", "", 
87, HbA1c, 2254, 2259, "HbA1c", "", 
88, Reduction, 2266, 2272, "0 . 89", "", "<http://ctro/data#Outcome_68049> <http://ctro/data#hasChangeValue> \"0 . 89\"."
89, SdErrorChangeValue, 2277, 2283, "0 . 17", "", "<http://ctro/data#Outcome_68049> <http://ctro/data#hasSdErrorChangeValue> \"0 . 17\"."
90, Percentage, 2284, 2285, "%", "", 
91, PValueChangeValue, 2288, 2302, "P  <  0 . 0001", "", "<http://ctro/data#Outcome_68049> <http://ctro/data#hasPValueChangeValue> \"P  <  0 . 0001\"."
92, EndPointDescription, 2307, 2321, "Adverse events", "", "<http://ctro/data#EndPointDescription_68077> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_68076> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_68077>."
6, Linagliptin, 2361, 2372, "linagliptin", "", 
50, Placebo, 2377, 2384, "placebo", "", 
94, PercentageAffected, 2396, 2402, "27 . 3", "", "<http://ctro/data#Outcome_68081> <http://ctro/data#hasPercentageAffected> \"27 . 3\"."
95, PercentageAffected, 2409, 2415, "28 . 0", "", "<http://ctro/data#Outcome_68108> <http://ctro/data#hasPercentageAffected> \"28 . 0\"."
211, EndPointDescription, 2459, 2473, "drug - related", "", "<http://ctro/data#EndPointDescription_68136> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_68135> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_68136>."
96, PercentageAffected, 2476, 2481, "2 . 4", "", "<http://ctro/data#Outcome_68140> <http://ctro/data#hasPercentageAffected> \"2 . 4\"."
97, PercentageAffected, 2488, 2493, "0 . 0", "", "<http://ctro/data#Outcome_68167> <http://ctro/data#hasPercentageAffected> \"0 . 0\"."
99, Hypoglycemia, 2515, 2527, "Hypoglycemia", "", "<http://ctro/data#Endpoint_68194> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
98, PercentageAffected, 2540, 2545, "1 . 0", "", "<http://ctro/data#Outcome_68199> <http://ctro/data#hasPercentageAffected> \"1 . 0\". <http://ctro/data#Outcome_68226> <http://ctro/data#hasPercentageAffected> \"1 . 0\"."
7, Linagliptin, 2577, 2588, "Linagliptin", "", 
101, ObservedResult, 2577, 2617, "Linagliptin therapy was weight neutral .", "", "<http://ctro/data#Outcome_68258> <http://ctro/data#hasObservedResult> \"Linagliptin therapy was weight neutral .\"."
100, BodyWeight, 2601, 2607, "weight", "", "<http://ctro/data#Endpoint_68253> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
8, Linagliptin, 2632, 2643, "Linagliptin", "", 
107, ConclusionComment, 2632, 2766, "Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .", "", "<http://ctro/data#ClinicalTrial_67884> <http://ctro/data#hasConclusionComment> \"Linagliptin 5   mg was efficacious and well tolerated over 24 weeks in Asian patients with T2DM inadequately controlled by metformin .\"."
102, DoseValue, 2644, 2645, "5", "", 
103, mg, 2648, 2650, "mg", "", 
104, Duration, 2691, 2699, "24 weeks", "", 
105, Ethnicity, 2703, 2708, "Asian", "", 
13, Type2Diabetes, 2723, 2727, "T2DM", "", 
19, Metformin, 2755, 2764, "metformin", "", 
108, PMID, 2921, 2929, "25753488", "", "<http://ctro/data#Publication_67877> <http://ctro/data#hasPMID> \"25753488\"."
